Gyre Therapeutics (GYRE) Accumulated Expenses (2010 - 2026)

Gyre Therapeutics (GYRE) has reported Accumulated Expenses for 17 consecutive years, with $15.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses fell 10.58% year-over-year to $15.4 million; the TTM figure through Mar 2026 stood at $15.4 million (down 10.58% YoY), while the FY2025 annual figure was $14.4 million, up 35.27% from the prior year.
• Accumulated Expenses advanced to $15.4 million in Q1 2026 per GYRE's latest filing, from $14.4 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $17.2 million in Q1 2025 and bottomed at $708000.0 in Q3 2023.
• Historically, Accumulated Expenses has averaged $8.4 million across 5 years, with a median of $10.5 million in 2024.
• Annual changes were most pronounced in 2022 — Accumulated Expenses slumped 63.79% — and 2024, when it jumped 1360.14%.
• Gyre Therapeutics' Accumulated Expenses stood at $9.3 million in 2022, then grew by 28.83% to $11.9 million in 2023, then declined by 11.06% to $10.6 million in 2024, then jumped by 35.27% to $14.4 million in 2025, then climbed by 7.35% to $15.4 million in 2026.
• Business Quant data shows GYRE's Accumulated Expenses at $15.4 million in Q1 2026, $14.4 million in Q4 2025, and $11.8 million in Q3 2025.